The renal cell carcinoma therapy market is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co) plus Inlyta (Pfizer) or Lenvima / Kisplyx (Eisai), and Opdivo plus Cabometyx (Exelixis / Ipsen) have revolutionized the treatment of advanced and metastatic disease and are becoming stalwarts in the first-line setting. The expected approvals of triplet combinations incorporating immune checkpoint inhibitors and tyrosine kinase inhibitors will further diversify the first-line setting. During the forecast period, the anticipated entry of Orpathys (AstraZeneca) and zanzalintinib (Exelixis) will provide effective first-line options specifically for patients with non-clear-cell histologies. The adjuvant setting will experience the most growth in the renal cell carcinoma market, as a result of Keytruda’s label expansion to and rapid adoption in the treatment of early-stage disease. Meanwhile, the approval of Welireg (Merck & Co.) is reshaping the treatment of Von-Hippel Lindau (VHL)-associated tumors.
Questions answered
How are the combinations of immune checkpoint inhibitors and tyrosine kinase inhibitors shaping the first-line treatment of advanced or metastatic renal cell carcinoma?
What is the expected market impact of Keytruda’s label expansion in the adjuvant setting?
Which are the most promising emerging regimens in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma market?
What are the drivers and constraints in the treatment of renal cell carcinoma, and how will the market evolve over the forecast period?
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Market share of drug classes for renal cell carcinoma: 2021
Market share of drug classes for renal cell carcinoma: 2031
Drug-treatable population share and major-market sales share in renal cell carcinoma: 2021
Drug-treatable population share and major-market sales share in renal cell carcinoma: 2031
Population positioning of current therapies in renal cell carcinoma
Population positioning of emerging therapies in renal cell carcinoma
Renal cell carcinoma SWOT analysis
Market drivers and constraints
What factors are driving the market for renal cell carcinoma?
What factors are constraining the market for renal cell carcinoma?
Major-market sales for renal cell carcinoma by drug-treatable population: 2021-2031
Major-market sales of immune oncology therapies for renal cell carcinoma: 2021-2031
Major-market sales of angiogenesis inhibitors for renal cell carcinoma: 2021-2031
Segment-specific trends
Patient-share dynamics of therapies for early-stage (stage I-III) renal cell carcinoma, United States: 2021-2031
Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, United States, 2021-2031
Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
Forecast
Market forecast assumptions
Market forecast dashboard
Etiology and pathophysiology
Disease overview
Progression of renal cell carcinoma
Anatomy and histology of renal cell carcinoma
Prognostic models for renal cell carcinoma
International Metastatic RCC Database Consortium risk assessment system for stage IV renal cell carcinoma
UCLA Integrated Staging System for renal cell carcinoma
Classification of renal cell carcinoma
Staging of renal cell carcinoma
TNM staging system for renal cell carcinoma
Definitions of the TNM staging system for renal cell carcinoma
Key pathways and drug targets for renal cell carcinoma
Epidemiology
Key findings
Epidemiology populations
Diagnosed incident cases of renal cell carcinoma: 2021-2031
Diagnosed incident cases of renal cell carcinoma by stage distribution: 2021-2031
Recurrent incident cases of renal cell carcinoma: 2021-2031
Renal cell carcinoma patient flow
Drug-Treatable Cases of Renal Cell Carcinoma: 2020-2030
Drug-treated cases of renal cell carcinoma: 2021-2031
Current treatment
Key findings
Treatment goals
Key endpoints used in clinical trials for renal cell carcinoma
Key current therapies
Overview
Mechanism of action of key current drug classes used for renal cell carcinoma
Current treatments used for renal cell carcinoma
Market events influencing the use of key current therapies in renal cell carcinoma
Key results from select clinical trials investigating Opdivo for the treatment of renal cell carcinoma
Ongoing clinical development of Opdivo
Key ongoing clinical trials of Opdivo in the treatment of renal cell carcinoma
Expert insight: Opdivo
Key results from select clinical trials investigating Opdivo and Yervoy combination therapy for the treatment of renal cell carcinoma
Ongoing clinical development of Opdivo and Yervoy combination therapy
Key ongoing clinical trials of Opdivo and Yervoy combination therapy in the treatment of renal cell carcinoma
Expert insight: Opdivo and Yervoy combination therapy
Key results from select clinical trials investigating Keytruda for the treatment of renal cell carcinoma
Ongoing clinical development of Keytruda
Key ongoing clinical trials of Keytruda in the treatment of renal cell carcinoma
Expert insight: Keytruda
Key results from select clinical trials investigating Bavencio for the treatment of renal cell carcinoma
Ongoing clinical development of Bavencio
Expert insight: Bavencio
Key results from select clinical trials investigating Sutent for the treatment of renal cell carcinoma
Expert insight: Sutent
Key results from select clinical trials investigating Votrient for the treatment of renal cell carcinoma
Expert insight: Votrient
Advantages and disadvantages of Nexavar
Expert insight: Nexavar
Key results from select clinical trials investigating Inlyta for the treatment of renal cell carcinoma
Expert insight: Inlyta
Expert insight: Avastin
Key results from select clinical trials investigating Cabometyx for the treatment of renal cell carcinoma
Ongoing clinical development of Cabometyx
Key ongoing clinical trials of Cabometyx in the treatment of renal cell carcinoma
Expert insight: Cabometyx
Key results from select clinical trials investigating Lenvima / Kisplyx for the treatment of renal cell carcinoma
Ongoing clinical development of Lenvima / Kisplyx
Expert insight: Lenvima / Kisplyx
Key results from select clinical trials investigating Fotivda for the treatment of renal cell carcinoma
Ongoing clinical development of Fotivda
Key ongoing clinical trials of Fotivda in the treatment of renal cell carcinoma
Expert insight: Fotivda
Advantages and disadvantages of Torisel
Expert insight: Torisel
Ongoing clinical development of Afinitor
Key ongoing clinical trials of Afinitor in the treatment of renal cell carcinoma
Expert insight: Afinitor
Key results from select clinical trials investigating Welireg for the treatment of renal cell carcinoma
Ongoing clinical development of Welireg
Key ongoing clinical trials of Welireg in the treatment of renal cell carcinoma
Expert insight: Welireg
Medical practice
Early-stage renal cell carcinoma: stages I-III
First-line advanced or metastatic renal cell carcinoma: stage IV
Second- and subsequent-line advanced or metastatic renal cell carcinoma
Patient characteristics influencing drug selection in renal cell carcinoma
Treatment decision tree for renal cell carcinoma: United States
Treatment decision tree for renal cell carcinoma: EU5
Treatment decision tree for renal cell carcinoma: Japan
Unmet need overview
Current and future attainment of unmet needs in renal cell carcinoma
Top unmet needs in renal cell carcinoma: current and future attainment
Expert insight: unmet need in renal cell carcinoma
Drug pipeline
Pipeline
Regulatory Milestones
Indication Comparison
Emerging therapies
Key findings
Key emerging therapies
Key therapies in development for renal cell carcinoma
Estimated market authorization dates of key emerging therapies for the treatment of renal cell carcinoma
Analysis of clinical development program for Tecentriq
Expert insight: Tecentriq
Expectations for market authorization and sales opportunity of Tecentriq in renal cell carcinoma
Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
Analysis of the clinical development program for Imfinzi
Key ongoing clinical trials of Imfinzi in the treatment of renal cell carcinoma
Expert insight: Imfinzi
Expectations for market authorization and sales opportunity of Imfinzi in renal cell carcinoma
Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
Analysis of clinical development program for tremelimumab and Imfinzi combination therapy
Key ongoing clinical trials of tremelimumab and Imfinzi combination therapy in the treatment of renal cell carcinoma
Expert insight: tremelimumab and Imfinzi combination therapy
Expectations for market authorization and sales opportunity of tremelimumab and Imfinzi combination therapy in renal cell carcinoma
Analysis of clinical development program for quavonlimab
Key ongoing clinical trials of quavonlimab in the treatment of renal cell carcinoma
Expert insight: quavonlimab
Expectations for market authorization and sales opportunity of quavonlimab in renal cell carcinoma
Key results from select clinical trials investigating Orpathys for the treatment of renal cell carcinoma
Analysis of clinical development program for Orpathys
Key ongoing clinical trials of Orpathys in the treatment of renal cell carcinoma
Expert insight: Orpathys
Expectations for market authorization and sales opportunity of Orpathys in renal cell carcinoma
Key results from select clinical trials investigating zanzalintinib for the treatment of renal cell carcinoma
Analysis of clinical development program for zanzalintinib
Key ongoing clinical trials of zanzalintinib in the treatment of renal cell carcinoma
Expectations for market authorization and sales opportunity of zanzalintinib in renal cell carcinoma
Key results from select clinical trials investigating abexinostat for the treatment of renal cell carcinoma
Analysis of clinical development program for abexinostat
Key ongoing clinical trials of abexinostat in the treatment of renal cell carcinoma
Expert insight: abexinostat
Expectations for market authorization and sales opportunity of abexinostat in renal cell carcinoma
Early-phase pipeline analysis
Select compounds in early-phase development for renal cell carcinoma
Access and reimbursement overview
Region-specific reimbursement practices
Key market considerations in renal cell carcinoma: United States
General reimbursement environment: United States
Key market access considerations in renal cell carcinoma: EU5
General reimbursement environment: EU5
Key market access considerations in renal cell carcinoma: Japan
General reimbursement environment: Japan
Appendix
Abbreviations
Renal cell carcinoma bibliography
Joan Tur, Ph.D.
Joan Tur, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Tur conducts market research and forecasting in a range of oncology indications. He has several years of experience as a pharmaceutical industry analyst with the Cortellis Competitive Intelligence group, serving as the team’s immuno-oncology expert. Prior to joining Clarivate, Dr. Tur was a researcher in inflammation and macrophage biology at the Barcelona Science Park. He holds a Ph.D. in biomedicine, an M.Sc. in immunology, and a B.Sc. in biology from the University of Barcelona.
Kiran Bountra
Kiran Bountra, M.Res., Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Bountra has a background in the biotechnology sector, specializing in target validation and small-molecule drug discovery. Before joining Clarivate, he worked as a senior scientist at OMass Therapeutics, with a focus on basal cell carcinoma and epilepsy programs. Previously, he trained as a structural biologist, researching the mechanisms of transport proteins involved in drug resistance. He holds a Ph.D. in biochemistry from Imperial College London.